In previous posts, we have commented on the July 2019 recall of Allergan Biocell breast implants. The Food and Drug Administration (FDA) issued a recall of the products due to their connection with breast implant illness and a rare form of cancer.
The link between certain types of breast implants and the risk of contracting anaplastic large cell lymphoma (ALCL) has been widely recognized by medical experts for quite some time. Recently there has been a marked increase in the number of cases of breast implant- associated (BIA) ALCL, specifically linked to Allergan products, leading ultimately to the FDA recall.
What does this mean to you? We hope to answer that question as thoroughly as possible. In addition, we want to inform you how Shamis & Gentile can help you if you have been affected by BIA-ALCL as a result of an Allergan breast implant.
BIA-ALCL is a type of lymphoma that develops as a result of specific types of breast implants. It is important to note that it is not a type of breast cancer. The risk of the disease has been associated with a number of Allergan’s silicone implant products, although it is not entirely certain how high the risk is of developing ALCL after receiving Allergan implants. While the condition remains rare, the FDA identified 573 cases of it worldwide – 33 of them fatal. Of these, 481 have been linked to Allergan products. This is a rate six times higher than products manufactured by any of Allergan’s competitors.
If you have Allergan breast implants, this does not automatically mean you are at risk of developing ALCL. The overall occurrence of the disease is still quite low; although the risk is higher than that of implants of a different brand. If, however, you or someone close to you has already developed ALCL and have one of these implants, then the chances of the condition having been caused by the Allergan products are significantly high, based on the FDA’s findings.